Imara-Logo-Color-RGB.jpg
Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
13 déc. 2021 07h00 HE | Imara, Inc.
BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...
logo.png
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results
12 mars 2020 07h05 HE | Corbus Pharmaceuticals Holdings, Inc.
Topline results for Phase 3 study in systemic sclerosis on schedule for summer of 2020 followed by Phase 2b study results in cystic fibrosis Completed $46 million public offering in February...
logo.png
Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
12 juin 2019 08h05 HE | Corbus Pharmaceuticals Holdings, Inc.
ACR CRISS score remains ≥ 0.95 (95%) at 21 months in systemic sclerosis open-label extension (OLE) studyCDASI activity score reaches -21.8 points at 16 months in dermatomyositis OLE study81% systemic...
CRBP-300-196.png
Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
08 nov. 2018 07h00 HE | Corbus Pharmaceuticals Holdings, Inc.
Licensed Jenrin Discovery’s extensive library of small molecules targeting the endocannabinoid system (ECS) positioning Corbus with the leading pipeline focused on treating inflammatory and fibrotic...